Clinical Application and Safety Monitoring of Revumenib (Menin Inhibitor) in Acute Leukemia

1. Precision Targeting Mechanism​

Revumenib is a novel oral inhibitor designed to disrupt the Menin-MLL1 interaction, specifically indicated for relapsed or refractory acute leukemias harboring KMT2A rearrangements or NPM1 mutations. By blocking the binding of Menin to MLL fusion proteins, it silences downstream leukemogenic gene expression, promoting differentiation or apoptosis of malignant cells. Due to its unique mechanism, familiarity with its specific adverse event profile is essential.

2. Vigilance for Differentiation Syndrome​

Clinicians must monitor for Differentiation Syndrome during treatment. Manifestations include fever, dyspnea, pulmonary infiltrates, weight gain, and hypotension. Upon suspicion, immediate administration of corticosteroids (e.g., dexamethasone) and temporary discontinuation of Revumenib are required. Early intervention typically leads to full reversal. Patient and caregiver education regarding these symptoms is mandatory during the initial cycles.

3. ECG and Electrolyte Management​

Revumenib can cause dose-dependent QTc interval prolongation, potentially increasing the risk of ventricular arrhythmias. Baseline and regular monitoring of electrocardiograms and electrolytes are mandatory. Serum potassium and magnesium should be maintained at the upper limit of the normal range. Concomitant use of other drugs known to prolong the QT interval should be avoided. If the QTc exceeds 500 ms or if syncope/ palpitations occur, treatment should be interrupted pending cardiac evaluation.

4. Hematologic and Gastrointestinal Reactions​

Common adverse events include mild to moderate nausea, vomiting, and diarrhea, which are generally manageable with standard antiemetics or antidiarrheals. Myelosuppression, including thrombocytopenia and neutropenia, is also frequent, necessitating transfusion support or infection prophylaxis based on blood counts. These toxicities often partially recover during treatment breaks, allowing for dose adjustments.

5. Long-Term Follow-Up and Risk Mitigation​

Given the current lack of ultra-long-term data, there may be risks of sustained immunosuppression and secondary infections, extrapolated from similar agents. Regular specialist follow-up is recommended even after therapy completion. Revumenib is restricted to use within specialized hematology-oncology centers under a strict Risk Evaluation and Mitigation Strategy (REMS), ensuring standardized protocols for patient safety.